MX2022010560A - Anticuerpos anti-adrenomedulina (anti-adm) que se unen al extremo nterminal libre para transición acelerada de adrenomedulina-glicin a (adm-gly) a bioadrenomedulina (bio-adm) en pacientes con relación de adm-gly/bio-adm por encima de un valor umbral y combinación con vitamina c. - Google Patents
Anticuerpos anti-adrenomedulina (anti-adm) que se unen al extremo nterminal libre para transición acelerada de adrenomedulina-glicin a (adm-gly) a bioadrenomedulina (bio-adm) en pacientes con relación de adm-gly/bio-adm por encima de un valor umbral y combinación con vitamina c.Info
- Publication number
- MX2022010560A MX2022010560A MX2022010560A MX2022010560A MX2022010560A MX 2022010560 A MX2022010560 A MX 2022010560A MX 2022010560 A MX2022010560 A MX 2022010560A MX 2022010560 A MX2022010560 A MX 2022010560A MX 2022010560 A MX2022010560 A MX 2022010560A
- Authority
- MX
- Mexico
- Prior art keywords
- adm
- gly
- seq
- bio
- sub
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title 1
- 229960005070 ascorbic acid Drugs 0.000 title 1
- 230000007704 transition Effects 0.000 title 1
- 206010007556 Cardiac failure acute Diseases 0.000 abstract 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 abstract 2
- 239000012634 fragment Substances 0.000 abstract 2
- 102000034567 proadrenomedullin Human genes 0.000 abstract 2
- 108010012004 proadrenomedullin Proteins 0.000 abstract 2
- 208000030090 Acute Disease Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 208000028399 Critical Illness Diseases 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 201000009906 Meningitis Diseases 0.000 abstract 1
- 102100026651 Pro-adrenomedullin Human genes 0.000 abstract 1
- 102400001018 Proadrenomedullin N-20 terminal peptide Human genes 0.000 abstract 1
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 abstract 1
- 206010040047 Sepsis Diseases 0.000 abstract 1
- 206010040070 Septic Shock Diseases 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001124 body fluid Anatomy 0.000 abstract 1
- 206010007625 cardiogenic shock Diseases 0.000 abstract 1
- 238000006243 chemical reaction Methods 0.000 abstract 1
- 210000002216 heart Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000003734 kidney Anatomy 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000010125 myocardial infarction Diseases 0.000 abstract 1
- 230000004768 organ dysfunction Effects 0.000 abstract 1
- PIRWNASAJNPKHT-SHZATDIYSA-N pamp Chemical compound C([C@@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)N)C(C)C)C1=CC=CC=C1 PIRWNASAJNPKHT-SHZATDIYSA-N 0.000 abstract 1
- 230000036303 septic shock Effects 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001144—Hormones, e.g. calcitonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
La presente invención está dirigida a un anticuerpo anti-adrenomedulina (ADM) o un fragmento de anticuerpo anti-ADM o andamio no Ig anti-ADM para ser utilizado en el tratamiento de un paciente críticamente enfermo que padece de una enfermedad o afección aguda que se selecciona a partir del grupo que comprende: infecciones graves (por ejemplo meningitis, síndrome de respuesta inflamatoria sistémica (SIRS), sepsis), choque (por ejemplo choque séptico, choque cardiogénico), insuficiencia cardiaca aguda (incluyendo insuficiencia cardiaca descompensada aguda, insuficiencia cardiaca crónica con empeoramiento de signos y síntomas), infarto al miocardio, apoplejía, disfunción de órgano (por ejemplo riñón, hígado, corazón, pulmón) o demencia con el fin de acelerar la conversión de la ADM-Gly a ADM-NH2 de la ADM-Gly circulante en dicho paciente, en el cual dicho paciente se caracteriza porque tiene una relación de pro-Adrenomedulina o un fragmento de la misma a ADM-NH2 (SEQ ID No. 20) por encima de un cierto umbral en una muestra de fluido corporal, en el cual dicha pro-Adrenomedulina o fragmento de la misma se selecciona a partir del grupo que consiste de PAMP (SEQ ID No. 32), MR- proADM (SEQ ID No. 33), ADM-Gly (SEQ ID No. 21) y CT-proADM (SEQ ID No. 34) y en el cual dicho anticuerpo anti-ADM o fragmento anti-ADM o andamio no Ig anti-ADM se une a la parte N-terminal y/o regional media (aminoácido 1-42) de ADM-Gly y/o ADM-NH2: YRQSMNNFQGLRSFGCRFGTCTVQKLAHQIYQFTDKDKDNVA (SEQ ID No. 23).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20159650.9A EP3871689A1 (en) | 2020-02-26 | 2020-02-26 | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| PCT/EP2021/054763 WO2021170763A1 (en) | 2020-02-26 | 2021-02-25 | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022010560A true MX2022010560A (es) | 2022-11-30 |
Family
ID=69740298
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022010560A MX2022010560A (es) | 2020-02-26 | 2021-02-25 | Anticuerpos anti-adrenomedulina (anti-adm) que se unen al extremo nterminal libre para transición acelerada de adrenomedulina-glicin a (adm-gly) a bioadrenomedulina (bio-adm) en pacientes con relación de adm-gly/bio-adm por encima de un valor umbral y combinación con vitamina c. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230357383A1 (es) |
| EP (2) | EP3871689A1 (es) |
| JP (1) | JP2023516171A (es) |
| KR (1) | KR20220145866A (es) |
| CN (1) | CN115279399A (es) |
| AU (1) | AU2021226987A1 (es) |
| BR (1) | BR112022016698A2 (es) |
| CA (1) | CA3169089A1 (es) |
| IL (1) | IL295770A (es) |
| MX (1) | MX2022010560A (es) |
| WO (1) | WO2021170763A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114782321B (zh) * | 2022-03-24 | 2022-12-06 | 北京医准智能科技有限公司 | 胸部ct影像选择方法、装置、设备及存储介质 |
| WO2025133235A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Adm-gly as marker for early predicting sepsis |
| WO2025133215A1 (en) * | 2023-12-22 | 2025-06-26 | Pam Theragnostics Gmbh | Use of inactive adrenomedullin precursor for therapeutic purposes |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| AU634716B2 (en) | 1988-08-01 | 1993-03-04 | Ciba Corning Diagnostics Corp. | Method for detection of an analyte using acridinium esters and liposomes |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0746609A4 (en) | 1991-12-17 | 1997-12-17 | Genpharm Int | NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES |
| JP2774769B2 (ja) | 1993-04-26 | 1998-07-09 | 賢治 寒川 | アドレノメデュリン |
| US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| CA2457520A1 (en) | 2001-08-30 | 2003-03-13 | Biorexis Pharmaceutical Corporation | Modified transferrin fusion proteins |
| EP2298278B1 (en) | 2002-06-07 | 2015-11-11 | Dyax Corp. | Prevention and reduction of blood loss and inflammatory response |
| US20050164301A1 (en) | 2003-10-24 | 2005-07-28 | Avidia Research Institute | LDL receptor class A and EGF domain monomers and multimers |
| US20100028995A1 (en) | 2004-02-23 | 2010-02-04 | Anaphore, Inc. | Tetranectin Trimerizing Polypeptides |
| CA2580881A1 (en) | 2004-09-21 | 2006-03-30 | Nascacell Technologies Ag | Use of microproteins as tryptase inhibitors |
| ES2373832T3 (es) | 2007-12-19 | 2012-02-09 | Affibody Ab | Polipéptido derivado de proteína a y capaz de unirse a pdgf. |
| BRPI0921469B1 (pt) | 2008-11-03 | 2022-01-18 | Molecular Partners Ag | Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica |
| US9376477B2 (en) | 2009-08-27 | 2016-06-28 | Covagen Ag | IL-17 binding compounds and medical uses thereof |
| US8921304B2 (en) | 2009-12-14 | 2014-12-30 | Scil Proteins Gmbh | Modified ubiquitin proteins having a specific binding activity for the extradomain B of fibronectin |
| RS58839B1 (sr) | 2010-06-08 | 2019-07-31 | Pieris Pharmaceuticals Gmbh | Muteini lipokalina u suzama koji vezuju il-4 r alfa |
| ES2938653T3 (es) | 2011-11-16 | 2023-04-13 | Adrenomed Ag | Anticuerpo antiadrenomedulina (ADM) o fragmento de anticuerpo anti-ADM o andamiaje no Ig anti-ADM para la prevención o la reducción de una disfunción orgánica o una insuficiencia orgánica en un paciente que presenta una enfermedad crónica o aguda o una afección aguda |
| IL283215B2 (en) | 2011-11-16 | 2024-05-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment and pharmaceutical compostions comprising the same |
| EP2780371B1 (en) | 2011-11-16 | 2018-10-24 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease |
| EP2594587B1 (en) * | 2011-11-16 | 2014-05-21 | AdrenoMed AG | Anti-Adrenomedullin (ADM) antibody or anti-ADM antibody fragment or anti-ADM non-Ig protein scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| CA2856142A1 (en) * | 2011-11-16 | 2013-05-23 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| KR20190120174A (ko) * | 2016-12-16 | 2019-10-23 | 아드레노메드 아게 | 울혈의 중재 및 치료가 필요한 환자에서 울혈의 중재 및 치료에 사용하기 위한 항-아드레노메둘린 (ADM) 항체 또는 항-ADM 항체 단편 또는 항-ADM 비-Ig 스캐폴드 |
| FI3687567T3 (fi) * | 2017-09-25 | 2025-01-08 | Adrenomed Ag | Adrenomedulliinin (adm) vasta-ainetta sitova aine käytettäväksi sairauden oireiden hoidossa tai ehkäisyssä |
| JP2021500548A (ja) * | 2017-10-18 | 2021-01-07 | アドレノメト アクチェンゲゼルシャフト | 抗アドレノメデュリン（ａｄｍ）結合剤での処置下での治療モニタリング |
| CN111902721B (zh) | 2018-02-08 | 2024-12-13 | 斯弗因高泰克有限公司 | 用于诊断和/或预测痴呆症的肾上腺髓质素和抗肾上腺髓质素结合物在治疗或预防痴呆症中的应用 |
-
2020
- 2020-02-26 EP EP20159650.9A patent/EP3871689A1/en not_active Withdrawn
-
2021
- 2021-02-25 AU AU2021226987A patent/AU2021226987A1/en active Pending
- 2021-02-25 KR KR1020227032718A patent/KR20220145866A/ko active Pending
- 2021-02-25 CN CN202180016916.4A patent/CN115279399A/zh active Pending
- 2021-02-25 CA CA3169089A patent/CA3169089A1/en active Pending
- 2021-02-25 JP JP2022551336A patent/JP2023516171A/ja active Pending
- 2021-02-25 BR BR112022016698A patent/BR112022016698A2/pt unknown
- 2021-02-25 WO PCT/EP2021/054763 patent/WO2021170763A1/en not_active Ceased
- 2021-02-25 EP EP21707993.8A patent/EP4110375A1/en active Pending
- 2021-02-25 IL IL295770A patent/IL295770A/en unknown
- 2021-02-25 US US17/802,164 patent/US20230357383A1/en active Pending
- 2021-02-25 MX MX2022010560A patent/MX2022010560A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN115279399A (zh) | 2022-11-01 |
| EP3871689A1 (en) | 2021-09-01 |
| US20230357383A1 (en) | 2023-11-09 |
| EP4110375A1 (en) | 2023-01-04 |
| BR112022016698A2 (pt) | 2022-11-16 |
| JP2023516171A (ja) | 2023-04-18 |
| AU2021226987A1 (en) | 2022-10-20 |
| CA3169089A1 (en) | 2021-09-02 |
| KR20220145866A (ko) | 2022-10-31 |
| WO2021170763A1 (en) | 2021-09-02 |
| IL295770A (en) | 2022-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022010560A (es) | Anticuerpos anti-adrenomedulina (anti-adm) que se unen al extremo nterminal libre para transición acelerada de adrenomedulina-glicin a (adm-gly) a bioadrenomedulina (bio-adm) en pacientes con relación de adm-gly/bio-adm por encima de un valor umbral y combinación con vitamina c. | |
| Stewart et al. | Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? | |
| Witthaut et al. | Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: impact of interleukin-6 and sepsis-associated left ventricular dysfunction | |
| Raghu et al. | Extracellular matrix in normal and fibrotic human lungs | |
| JP5379018B2 (ja) | 新規な診断マーカーであるｃｔ−プロａｄｍによる診断および危険性の層化 | |
| US8283318B2 (en) | Aquaretic and natriuretic polypeptides lacking vasodilatory activity | |
| CN101641601B (zh) | 用于bnp免疫测定法的稳定标准品 | |
| US8507209B2 (en) | Biomarkers | |
| EP2118668B1 (en) | Method of determining equine nt-probnp. | |
| Bomberg et al. | Presepsin (sCD14-ST) is a novel marker for risk stratification in cardiac surgery patients | |
| Fan et al. | Biomarkers for acute cardiorenal syndrome | |
| Keranov et al. | CILP1 as a biomarker for right ventricular maladaptation in pulmonary hypertension | |
| US10106575B2 (en) | Biomarkers | |
| CN110167962B (zh) | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 | |
| Buendgens et al. | Midregional Proadrenomedullin (MRproADM) Serum Levels in Critically Ill Patients Are Associated with Short‐Term and Overall Mortality during a Two‐Year Follow‐Up | |
| Nishikimi et al. | Different secretion patterns of adrenomedullin, brain natriuretic peptide, and atrial natriuretic peptide during exercise in hypertensive and normotensive subjects | |
| Akashi et al. | Atrial natriuretic peptide and related peptides. | |
| Gao et al. | Cysteine-rich 61 (Cyr61) upregulated in pulmonary arterial hypertension promotes the proliferation of pulmonary artery smooth muscle cells | |
| Lee et al. | Novel biomarkers for cardio-renal syndrome | |
| US12000841B2 (en) | Diagnostic kits and methods configured to rapidly and non-invasively determine physiologic levels of galactose-deficient IgA1 (Gd-IgA1) in the subject of IgA nephropathy | |
| JP2022031783A (ja) | ＡＰＰ６６９－ｘのＮ末端を特異的に認識する抗体、及び免疫測定法 | |
| Michel et al. | Impact of the Fontan operation on organ systems | |
| Barbandi et al. | A case series of reversible acute cardiomyopathy associated with H1N1 influenza infection | |
| Maddipati et al. | Pulmonary hypertension in chronic kidney disease and end-stage renal disease | |
| JP2023507738A (ja) | 線維症の評価および処置のための方法および組成物 |